We founded Azento Health on a simple belief: the breakthrough in obesity treatment should be matched by a breakthrough in how we support people throughout their weight-loss journey.
Better Weight Loss.
Our purpose
To enhance overall health and contribute to better obesity care through optimised gut health, microbiome science and practical companion solutions.
Our mission
To build Better Weight Loss by developing science-led companion products that support health, wellbeing and the changing needs of people on modern weight-loss journeys.
From insight to evidence — fast.
Azento Health was created around the changing needs emerging from modern obesity treatment. We identified the opportunity. We built a defined microbiome platform. We developed Forte80®. We launched the product. We completed a randomized clinical study. We generated real-world patient experience. And we are using those learnings to build a broader pipeline.
01
Insight
02
Product
03
Evidence
04
Platform
That combination of scientific curiosity, commercial focus and execution speed defines how we work.
Big-company experience. Specialist focus. Entrepreneurial speed.
Our leadership team combines experience across obesity and GLP-1 medicines, pharmaceutical commercialisation, microbiome and biotics, nutrition, consumer health, clinical development and entrepreneurship.
Leadership team
Mads Stoustrup
CEO & Co-Founder
Over 20 years at Novo Nordisk across GLP-1 therapies, obesity treatment and business building.
Dr. Peter Kaufmann
CCO, CSO & Co-Founder
25+ years in pharma and nutrition, PhD from ETH Zurich and extensive CEO experience.
Jesper N. Gantzel
Chairman & Co-Founder
20+ years building businesses, including ventures and exits in probiotics and microbiome science.
Remy Kindle
Sales Director
25+ years across obesity, diabetes and cardiovascular care.
Tzvetanka (Tzvety) Nikolova
Business Development Director
Building businesses across health and nutrition markets.
Scientific advisors
Professor Arne Astrup
MD, DMSc (DK)
World-leading researcher in nutrition and obesity and co-discoverer of GLP-1’s role as a satiety hormone.
Professor Stephen Gough
MD, FRCP (UK)
World-leading clinician and pharmaceutical leader in diabetes, obesity and GLP-1-based therapies, with senior leadership experience from Oxford and Novo Nordisk.
Scientific expertise that drives innovation.
Azento Health collaborates with experienced scientific and clinical experts across obesity medicine, nutrition, GLP-1 therapies, microbiome science and clinical development.
Their expertise goes beyond advice. They challenge assumptions, strengthen clinical research and help identify unmet patient needs — turning scientific insights into meaningful product innovation.
Partnerships and collaborations
Let’s build Better Weight Loss together.
For companies, clinics, pharmacies and researchers — in distribution, product development, research collaboration and clinical projects.
